A detailed evaluation of the effect of dupilumab on sleep in adults with atopic dermatitis
- PMID: 37658831
- DOI: 10.1093/bjd/ljad320
A detailed evaluation of the effect of dupilumab on sleep in adults with atopic dermatitis
Conflict of interest statement
Conflicts of interest E.Y.L. has received speaker honoraria from Sanofi and AstraZeneca. A.M.D. has received compensation from the British Journal of Dermatology (Section Editor), the American Academy of Dermatology (guidelines writer), the National Eczema Association (grant reviewer), Canadian Dermatology Today (manuscript writer) and the Canadian Agency for Drugs and Technologies in Health (consultant). A.M.D. has received research grants to his institution from the National Eczema Association, Eczema Society of Canada, the Canadian Dermatology Foundation, the Canadian Institutes for Health Research, US National Institutes of Health and the Physicians Services Incorporated Foundation.
Comment on
-
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.Br J Dermatol. 2023 Nov 16;189(6):685-694. doi: 10.1093/bjd/ljad284. Br J Dermatol. 2023. PMID: 37562034 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
